Not logged in.png)
Share.png)
SaveInvestigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS)
Okuda, Yusuke; Mikami, Naoaki; Hamada, Riku; Hataya, Hiroshi; Tanaka, Kazuki; Terano, Chikako; Fujita, Naoya; Miura, Kenichiro; Ishizuka, Kiyonobu; Shirai, Yoko; Kamei, Koichi; Ogura, Masao; Okamoto, Takayuki; Suzuki, Ryota; Shinozuka, Shunsuke; Shima, Yuko; Oka, Masafumi; Shimabukuro, Wataru; Tsukaguchi, Hiroyasu; Inagaki, Tetsuji; Nishiyama, Kei; Hashimoto, Taeko; Ito, Naoko; Yamamura, Tomohiko; Horinouchi, Tomoko; Ishikura, Kenji; Nakanishi, Koichi; Nozu, Kandai Share Save Share Save Frequent copy number gain of MCL1 is a therapeutic target for osteosarcomaTakagi, Satoshi; Nakajima, Mikako; Koike, Sumie; Takami, Miho; Sugiura, Yoshiya; Sakata, Seiji; Baba, Satoko; Takemoto, Ai; Huang, Tianyi; Seto, Yosuke; Saito, Masanori; Funauchi, Yuki; Ae, Keisuke; Takeuchi, Kengo; Fujita, Naoya; Katayama, Ryohei Share Save In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissuesTakahashi, Yuki; Morimura, Rii; Tsukamoto, Kei; Gomi, Sayaka; Yamada, Asuka; Mizukami, Miki; Naito, Yasuyuki; Irie, Shinji; Nagayama, Satoshi; Shinozaki, Eiji; Yamaguchi, Kensei; Fujita, Naoya; Kitano, Shiro; Katayama, Ryohei; Matsusaki, Michiya Share Save Share Save A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancerSuzuki, Mai; Uchibori, Ken; Oh-hara, Tomoko; Nomura, Yumi; Suzuki, Ryusei; Takemoto, Ai; Araki, Mitsugu; Matsumoto, Shigeyuki; Sagae, Yukari; Kukimoto-Niino, Mutsuko; Kawase, Yusuke; Shirouzu, Mikako; Okuno, Yasushi; Nishio, Makoto; Fujita, Naoya; Katayama, Ryohei Share Save Share Save Share Save Share Save Share Save Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinomaShimizu, Yuki; Maruyama, Kohei; Suzuki, Mai; Kawachi, Hiroshi; Low, Siew-Kee; Oh-hara, Tomoko; Takeuchi, Kengo; Fujita, Naoya; Nagayama, Satoshi; Katayama, Ryohei Share Save Targeting Podoplanin for the Treatment of OsteosarcomaTakemoto, Ai; Takagi, Satoshi; Ukaji, Takao; Gyobu, Nobuhiko; Kakino, Mamoru; Takami, Miho; Kobayashi, Asami; Lebel, Marie; Kawaguchi, Tokuichi; Sugawara, Minoru; Tsuji-Takayama, Kazue; Ichihara, Kenji; Funauchi, Yuki; Ae, Keisuke; Matsumoto, Seiichi; Sugiura, Yoshiya; Takeuchi, Kengo; Noda, Tetsuo; Katayama, Ryohei; Fujita, Naoya Share Save GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancerShimizu, Yuki; Okada, Koutaroh; Adachi, Jun; Abe, Yuichi; Narumi, Ryohei; Uchibori, Ken; Yanagitani, Noriko; Koike, Sumie; Takagi, Satoshi; Nishio, Makoto; Fujita, Naoya; Katayama, Ryohei Share Save Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationSagawa, Ray; Sakata, Seiji; Gong, Bo; Seto, Yosuke; Takemoto, Ai; Takagi, Satoshi; Ninomiya, Hironori; Yanagitani, Noriko; Nakao, Masayuki; Mun, Mingyon; Uchibori, Ken; Nishio, Makoto; Miyazaki, Yasunari; Shiraishi, Yuichi; Ogawa, Seishi; Kataoka, Keisuke; Fujita, Naoya; Takeuchi, Kengo; Katayama, Ryohei Share Save Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasisTakagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Kawaguchi, Tokuichi; Sugawara, Minoru; Saito, Masanori; Funauchi, Yuki; Ae, Keisuke; Matsumoto, Seiichi; Fujita, Naoya; Katayama, Ryohei Share Save Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivityYoshizawa, Takahiro; Uchibori, Ken; Araki, Mitsugu; Matsumoto, Shigeyuki; Ma, Biao; Kanada, Ryo; Seto, Yosuke; Oh-hara, Tomoko; Koike, Sumie; Ariyasu, Ryo; Kitazono, Satoru; Ninomiya, Hironori; Takeuchi, Kengo; Yanagitani, Noriko; Takagi, Satoshi; Kishi, Kazuma; Fujita, Naoya; Okuno, Yasushi; Nishio, Makoto; Katayama, Ryohei Share Save Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancerMizuta, Hayato; Okada, Koutaroh; Araki, Mitsugu; Adachi, Jun; Takemoto, Ai; Kutkowska, Justyna; Maruyama, Kohei; Yanagitani, Noriko; Oh-hara, Tomoko; Watanabe, Kana; Tamai, Keiichi; Friboulet, Luc; Katayama, Kazuhiro; Ma, Biao; Sasakura, Yoko; Sagae, Yukari; Kukimoto-Niino, Mutsuko; Shirouzu, Mikako; Takagi, Satoshi; Simizu, Siro; Nishio, Makoto; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei Share Save TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathwaysMiura, Akihiro; Sootome, Hiroshi; Fujita, Naoya; Suzuki, Takamasa; Fukushima, Hiroto; Mizuarai, Shinji; Masuko, Norio; Ito, Kimihiro; Hashimoto, Akihiro; Uto, Yoshihiro; Sugimoto, Tetsuya; Takahashi, Hidekazu; Mitsuya, Morihiro; Hirai, Hiroshi Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
